BidaskClub downgraded shares of AtriCure, Inc. (NASDAQ:ATRC) from a strong-buy rating to a buy rating in a research report released on Monday, July 24th.
ATRC has been the topic of a number of other reports. Zacks Investment Research cut AtriCure from a buy rating to a hold rating in a research report on Wednesday, May 10th. Needham & Company LLC reiterated a buy rating and issued a $25.00 price target (up from $23.00) on shares of AtriCure in a research report on Friday, May 5th. Canaccord Genuity reiterated a buy rating and issued a $22.00 price target on shares of AtriCure in a research report on Monday, April 17th. Leerink Swann reiterated an outperform rating and issued a $26.00 price target on shares of AtriCure in a research report on Friday, June 16th. Finally, ValuEngine upgraded AtriCure from a sell rating to a hold rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $25.00.
AtriCure (ATRC) traded up 0.75% during trading on Monday, reaching $22.80. 207,124 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $23.72 and its 200-day moving average price is $20.54. AtriCure has a 52-week low of $14.36 and a 52-week high of $25.18. The company’s market capitalization is $782.82 million.
AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $45.23 million for the quarter, compared to analysts’ expectations of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. AtriCure’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) earnings per share. Equities analysts expect that AtriCure will post ($0.95) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/12/atricure-inc-nasdaqatrc-downgraded-by-bidaskclub-to-buy-updated-updated.html.
In other news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total transaction of $214,400.00. Following the sale, the director now owns 24,162 shares in the company, valued at $518,033.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in ATRC. US Bancorp DE boosted its stake in shares of AtriCure by 152.1% in the second quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock valued at $102,000 after buying an additional 2,535 shares during the last quarter. Sei Investments Co. boosted its stake in shares of AtriCure by 75.5% in the second quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock valued at $168,000 after buying an additional 2,983 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of AtriCure by 1.2% in the first quarter. Bank of Montreal Can now owns 10,462 shares of the medical device company’s stock valued at $200,000 after buying an additional 128 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of AtriCure by 3.8% in the second quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock valued at $208,000 after buying an additional 312 shares during the last quarter. Finally, Rockefeller Financial Services Inc. boosted its stake in shares of AtriCure by 185.0% in the first quarter. Rockefeller Financial Services Inc. now owns 11,766 shares of the medical device company’s stock valued at $225,000 after buying an additional 7,637 shares during the last quarter. Institutional investors own 84.94% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.